Question 29

- Which of the following is incorrect regarding hemorrhagic complications associated with the use of vorapaxar, a PAR1 antagonist used for secondary prevention in patients with established PAD?
  a. The beneficial effects of PAR1 antagonism on limb vascular events is accompanied by an increased risk of bleeding
  b. Compared with placebo, in the PAD cohort, vorapaxar increased the risk of bleeding, including GUSTO moderate or severe bleeding
  c. The rates of intracranial and fatal hemorrhages with vorapaxar were similar to placebo
  d. GUSTO moderate or severe bleeding with vorapaxar in the PAD cohort was higher for those on thienopyridine

Question 29

- Which of the following is incorrect regarding hemorrhagic complications associated with the use of vorapaxar, a PAR1 antagonist used for secondary prevention in patients with established PAD?
  a. The beneficial effects of PAR1 antagonism on limb vascular events is accompanied by an increased risk of bleeding
  b. Compared with placebo, in the PAD cohort, vorapaxar increased the risk of bleeding, including GUSTO moderate or severe bleeding
  c. The rates of intracranial and fatal hemorrhages with vorapaxar were similar to placebo
  d. GUSTO moderate or severe bleeding with vorapaxar in the PAD cohort was higher for those on thienopyridine

Vorapaxar in Patients With PAD: Results From TRA2°P-TIMI 50

Hemorrhagic complications of vorapaxar

Endpoint	Vorapaxar (n=1892), (%)	Placebo (n=1895) , (%)	HR; 95%CI	p
GUSTO mod/severe bleed	7.4%	4.5%	1.62 (1.21–2.18)	0.001
GUSTO severe bleed	2.4%	1.6%	1.41 (0.85–2.34)	0.018
Fatal bleed	0.5%	0.4%	1.02 (0.36–2.90)	0.98
ICH	0.9%	0.4%	2.03 (0.82–5.02)	0.13
ICH (excluding patients with prior cerebrovascular disease)	0.7%	0.4%	1.66 (0.54–5.08)	0.37

Risk of GUSTO moderate or severe bleeding did not differ on the basis of the use of aspirin at baseline (*p* interaction=0.20 or with background dual antiplatelet therapy (p interaction=0.403)

Bonaca *et al*. Circulation. 2013;127:1522-1529